Cyber Monday saleUp to 70% OFF
Estrella Immunopharma, Inc.Estrella Immunopharma, Inc.Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

ESLA fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ESLA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company